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Weight gain and body mass index (BMI) increase are cen-
tral issues in patients living with HIV who need to minimize 
the risk of metabolic disease. Information collected through 
the SCOLTA cohort revealed significant 1-year BMI increase 
in patients treated with dolutegravir (P  =  .004), raltegravir 
(P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and 
rilpivirine (P  =  .029). BMI gain correlated with low baseline 
BMI (P = .002) and older age (P = .0007) in Centers for Disease 
Control and Prevention stages A/B, with lower BMI (P = .005) 
and CD4+ T-cell count (P = .007) at enrollment in stage C.
Keywords. ART; BMI; cardiovascular risk; darunavir; 
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People living with HIV (PLWHIV) are at higher risk of car-
diovascular disease (CVD) when compared with the HIV-
uninfected population [1], and for this reason, the control and 
correction of modifiable risk factors for CVD and metabolic dis-
ease, including body mass index (BMI) and weight, are crucial 
[2]. Previous studies did not find a direct correlation between 
higher BMI and risk of myocardial infarction (MI) in PLWHIV 
[3, 4], but on the other hand, higher BMI is a recognized risk 
factor for diabetes mellitus [5, 6], which in turn is a risk factor 
for MI in the general population and also in PLWHIV [7].
Combined antiretroviral therapy (cART) can be associated 
with weight changes, and on-cART weight gain has also been 
demonstrated as a risk factor for incident diabetes in PLWHIV 
[8]. Recent reports have highlighted a possible role of dolute-
gravir (DTG) in weight gain [9, 10] and body fat composition 
changes during raltegravir (RAL) treatment [11], which made us 
ask if integrase inhibitors (INSTIs) could potentially have a class 
effect in fat gain. However, these previous works did not adjust 
the final weight gain for initial BMI and advanced disease, intro-
ducing possible confounders in the interpretation of the results.
We reviewed all the data of patients enrolled in the obser-
vational SCOLTA project [12] and who started a regimen con-
taining RAL, DTG, elvitegravir (EVG), darunavir (DRV), or 
rilpivirine (RPV). Patients enrolled in SCOLTA were prospec-
tively followed up with the aim of identifying possible drug-re-
lated adverse events, and every 6 months, laboratory and clinical 
data, including body weight, are collected. The study protocol of 
the SCOLTA cohort was approved by local ethical committees, 
and written consent was obtained from all participants.
In order to minimize possible confounders, we decided to 
exclude naïve patients and experienced subjects with no ther-
apy before enrollment. Globally, 755 cART-experienced patients 
with at least 1 year of follow-up while on the same therapy were 
included in the analysis (225 in DTG, 382 in RAL, and 148 in 
EVG). As control groups, we also analyzed 145 patients on a treat-
ment including DRV without INSTI and 218 patients on RPV.
Overall, the median age of 1118 patients was 46.0  years 
(range, 19–81 years). Patients were 71.2% male, 19.2% had base-
line CD4+ T-cell count <200 cells/μL, 38.1% were in Centers 
for Disease Control and Prevention (CDC) stage A, 30.5% were 
in CDC stage B, and 31.4% were in CDC stage C, and 39.9% 
had detectable HIV-RNA (>50 copies/dl) at the start of the new 
regimen. Of them, 71.5% were on a previous failing PI-based 
cART. The median time of previous cART was 10.8 years (range, 
1 month–30.6 years). As regards BMI, 5.9% were underweight 
(BMI < 18.50), 60.5% were normal weight (BMI, 18.50–24.99), 
27.0% were overweight (BMI, 25.00–29.99), and 6.6% were 
obese (BMI ≥ 30.00). The median BMI was 23.7 (range, 12.5–
39.1); 31.0% had lipodystrophy or lipoatrophy at study entry.
In the whole population (any cART), there was a BMI change 
of +0.19 (±standard error, 0.03) at 6 months and +0.25 (±0.04) 
at 12  months (both P  <  .0001). At univariate analysis, all the 
considered treatments but RPV were associated with slight but 
statistically significant BMI rise at 1-year follow-up (Table 1). 
However, no direct comparison between the 2 control drugs 
and any INSTI was significant.
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To account for potential confounders, we used a general linear 
model multivariate analysis to evaluate whether BMI changes at 
6-month and 12-month visits were significantly different from 0 
in all cohorts. Comparisons were planned among single INSTIs 
and control cohorts. We also planned to simultaneously control 
for several factors potentially associated with weight gain, and 
we recorded the following at enrollment: sex (M/F), age (as a 
continuous variable), CD4+ T-cell count (<200 vs ≥200), CDC 
stage (A+B vs C), HIV-RNA (3 categories: <50, 50–1000, >1000 
copies/mL), lipodystrophy/lipoatrophy (Y/N), cART duration 
(<3 or ≥3  years), and initial BMI class. After adjustment, the 
1-year BMI modification was confirmed significantly different 
from 0 in all the study drugs. Again, no INSTI was significantly 
different from DRV or RPV in the adjusted analysis, whereas 
age at study entry (P = .016), BMI at enrollment (P = .011), and 
CD4 <200 cells/mL (P = .006) were significantly associated to 
BMI changes. Adjusted means are shown in Table 1.
To better understand the role of cohort drugs on BMI vari-
ation, we reran the multivariate analyses in strata of variables 
that could indicate the current clinical status of patients. CDC 
stage (A+B or C). At 12 months, patients in stage A+B (n = 767, 
of which 20.7% were in DTG, 30.2% were in RAL, 14.5% were in 
EVG, 11.1% were in DRV, and 23.5% were in RPV) experienced 
a mean BMI increase of 0.13 (±0.06), which was related to lower 
BMI at enrollment (P =  .002) and older age (P =  .0007). BMI 
increase was significantly different from 0 in EVG and DRV. 
As compared with DRV, RAL patients had a significantly lower 
BMI modification (P = .038), but no other significant difference 
was observed. Focusing instead on patients in CDC stage C 
(n = 351, 18.8% in DTG, 42.7% in RAL, 10.5% in EVG, 17.1% in 
DRV, and 10.8% in RPV), the mean BMI increase at 12 months 
was 0.46 (±0.08) and was correlated with BMI (P =  .005) and 
CD4+ at enrollment (P  =  .007). In this group, DTG, RAL, 
DRV, and RPV use was correlated with BMI increase (Table 1). 
Indeed, it is possible that in the EVG cohort, the sample size was 
too small and the effect, less marked than that observed in more 
used drugs, too low to achieve significance.
To further investigate the effect of other clinical varia-
bles, we also repeated the analysis, stratifying patients on the 
basis of baseline CD4+ T-cell count and years of cART. Using 
CD4+ level at enrollment as an indicator of advanced disease, 
instead of CDC stage, BMI increases were consistently similar 
in subjects without and with advanced disease, through drug 
cohorts (Table  1). Moreover, patients with a history of cART 
≥3  years experienced a significant BMI increase with all the 
drug regimens (Table  1). BMI increase was also observed in 
Table  1. BMI Changes in 1118 Patients on Dolutegravir, Raltegravir, Elvitegravir, Darunavir, or Rilpivirine, Before and After Adjustment for Baseline 
Characteristics, and After Stratification for CDC Stage of Disease, CD4+ at Baseline, Previous ART Duration
BMI, mean ± SE, kg/m2
Dolutegravir Raltegravir Elvitegravir Darunavir Rilpivirine
N = 225 N = 382 N = 148 N = 145 N = 218
6-mo visit 0.18 ± 0.08 0.17 ± 0.07 0.21 ± 0.07 0.32 ± 0.09 0.06 ± 0.07
P = .016 P = .014 P = .004 P = .0009 P = .39
12-mo visit 0.30 ± 0.10 0.24 ± 0.08 0.23 ± 0.10 0.41 ± 0.10 0.06 ± 0.08
P = .005 P = .003 P = .017 P = .0001 P = .51
6-mo visita 0.28 ± 0.10 0.26 ± 0.08 0.42 ± 0.11 0.35 ± 0.11 0.30 ± 0.11
P = .006 P = .001 P = .0003 P = .001 P = .005
12-mo visita 0.37 ± 0.13 0.36 ± 0.10 0.42 ± 0.15 0.48 ± 0.14 0.30 ± 0.14
P = .004 P = .0004 P = .004 P = .0006 P = .029
12-mo visit, in strata of:
CDC stage A+Bb 0.22 ± 0.15 0.02 ± 0.12 0.38 ± 0.156 0.36 ± 0.16 0.10 ± 0.15
n = 767 P = .16 P = .90 P = .019 P = .029 P = .51
CDC stage Cb 0.66 ± 0.24 0.86 ± 0.19 0.29 ± 0.30 0.64 ± 0.25 0.63 ± 0.31
n = 351 P = .007 P < .0001 P = .35 P = .012 P = .04
CD4+ ≥200 cells/mLc 0.15 ± 0.14 0.16 ± 0.11 0.33 ± 0.15 0.45 ± 0.16 0.10 ± 0.14
n = 903 P = .28 P = .17 P = .031 P = .005 P = .46
CD4+ <200 cells/mLc 1.24 ± 0.41 0.70 ± 0.25 0.08 ± 0.44 0.46 ± 0.31 1.34 ± 0.66
n = 215 P = .003 P = .006 P = .85 P = .14 P = .044
Previous ART <3 yd 0.68 ± 0.42 0.78 ± 0.35 0.32 ± 0.42 1.42 ± 0.51 0.08 ± 0.40
n = 195 P = .11 P = .029 P = .45 P = .006 P = .85
Previous ART ≥3 yd 0.34 ± 0.13 0.32 ± 0.09 0.50 ± 0.16 0.38 ± 0.13 0.36 ± 0.14
n = 921 P = .009 P = .0007 P = .001 P = .004 P = .011
P refers to change from baseline: if P < .05, means are significantly different from 0.
aAdjusted for sex, age, CD4+, detectable viral load, CDC stage, duration of ART, lipodystrophy, and BMI at study entry.
bAdjusted for sex, age, CD4+, detectable viral load, duration of ART, lipodystrophy, and BMI at study entry.
cAdjusted for sex, age, detectable viral load, CDC stage, duration of ART, lipodystrophy, and BMI at study entry.
dAdjusted for sex, age, CD4+, detectable viral load, CDC stage, lipodystrophy, and BMI at study entry.
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the group with shorter cART duration, but due to lower sam-
ple size (n = 195), this change did not achieve statistical signifi-
cance; however, in our cohorts, the direct adjusted comparison 
between these groups did not highlight a significant difference.
Finally, we performed an analysis in strata of HIV-RNA (<50, 
50–1000, >1000 copies/mL). BMI change by HIV-RNA load 
was U-shaped, with a minimum in subjects with 50–999 cop-
ies/mL, but without significant differences among strata after 
adjustment for other variables.
While in previous studies performed on the general population, 
a BMI increase was found more likely in people with normal BMI 
or overweight [13], we found in PLWHIV a higher BMI gain in 
those who had lower baseline values. Moreover, in the European 
population, the proportion of overweight is higher in more 
advanced ages [14]. In our cohort, a link between age and BMI 
was confirmed in CDC stages A+B, while in patients with more 
advanced stage disease, only the lower baseline BMI and CD4+ 
T-cell count were linked to significant BMI increases, independ-
ent of chronological age. The correlation between BMI change 
and low CD4+ T-cell counts was already found in previous studies 
[15] and was confirmed by our data, which might suggest a role 
of nutritional rehabilitation following weight loss from advanced 
disease. Finally, previous studies demonstrated that the greatest 
increase in BMI occurred in the first year of therapy [15], while 
here a significant increase was demonstrated also in patients who 
had already been in treatment for more than 3 years.
The study has possible biases related to its observational 
design. Indeed, patients taking different drugs had different 
baseline characteristics and were enrolled in different years. 
Moreover, data on personal choices or sociopsychological con-
ditions influencing weight loss or gain were not recorded, limit-
ing the generalizability of these data. With these limitations, our 
study found that a BMI increase can be observed in PLWHIV 
taking cART, also after many years of treatment and especially 
in those with lower baseline BMI. An age-related BMI increase, 
independent of exposure to cART, can partially justify this find-
ing in CDC stages A+B, while patients in stage C have significant 
increases independent from their age. Patients in stage C who 
were in treatment with DTG, RAL, DRV, and RPV also had sig-
nificant increases, independent from baseline BMI. In our study, 
there was not a significant difference among patients in differ-
ent antiretroviral drugs, including integrase inhibitors. To assess 
the role of single drugs, studies with fewer confounders and 
adequate sample size in different drug classes are still needed.
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